These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7114798)

  • 1. Activation of the alternative pathway of complement by immune complexes and degradation of these complexes by macrophages.
    Daha MR
    Ann Immunol (Paris); 1982; 133C(2):245-52. PubMed ID: 7114798
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhanced alternative complement pathway-dependent degradation of soluble immunoglobulin aggregates by macrophages.
    Daha MR; Van Es LA
    Immunology; 1981 Jul; 43(3):513-8. PubMed ID: 7251062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus.
    Garred P; Mollnes TE; Thorsteinsson L; Erlendsson K; Steinsson K
    Scand J Immunol; 1990 Jan; 31(1):59-64. PubMed ID: 2300790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes.
    Pfaffenbach G; Lamm ME; Gigli I
    J Exp Med; 1982 Jan; 155(1):231-47. PubMed ID: 7054357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes.
    Garred P; Michaelsen TE; Aase A; Mollnes TE
    J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
    Takata Y; Tamura N; Fujita T
    J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of antibody isotype on the activation of C3 and C4 by immune complexes formed in the presence of serum: correlation with the prevention of immune precipitation.
    Stewart WW; Johnson A; Steward MW; Whaley K; Kerr MA
    Mol Immunol; 1990 May; 27(5):423-8. PubMed ID: 2366759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C3 binds covalently to the C gamma 3 domain of IgG immune aggregates during complement activation by the alternative pathway.
    Antón LC; Alcolea JM; Sánchez-Corral P; Marqués G; Sánchez A; Vivanco F
    Biochem J; 1989 Feb; 257(3):831-8. PubMed ID: 2784671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating immune complexes, complement factors C3, C4, C1-inhibitor, alpha-1-antitrypsin and immunoglobulins in asthmatic patients.
    Häfner GE; Wüthrich B; Grob PJ; Arrenbrecht S
    Respiration; 1981; 41(4):248-57. PubMed ID: 6975491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of rat complement by soluble and insoluble immune complexes of rat IgA.
    Rits M; Hiemstra PS; Bazin H; van Es LA; Daha M; Vaerman JP
    Monogr Allergy; 1988; 24():129-33. PubMed ID: 3362139
    [No Abstract]   [Full Text] [Related]  

  • 11. Solubilization of immune precipitates by six isolated alternative pathway proteins.
    Fujita T; Takata Y; Tamura N
    J Exp Med; 1981 Dec; 154(6):1743-51. PubMed ID: 6459396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of complement activity by immunoglobulin. I. Effect of immunoglobulin isotype on C4 uptake on antibody-sensitized sheep erythrocytes and solid phase immune complexes.
    Miletic VD; Hester CG; Frank MM
    J Immunol; 1996 Jan; 156(2):749-57. PubMed ID: 8543829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement-dependent inhibition of degradation of soluble immune complexes and immunoglobulin aggregates by thioglycollate-stimulated peritoneal macrophages.
    Daha MR; Van Es LA
    Immunology; 1983 Sep; 50(1):107-11. PubMed ID: 6224740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolism of C3 and C4 in patients with immune complexes and normal complement levels.
    Charlesworth JA; Peake PW; Golding J; Pussell BA; Timmermans V; Wicks I; Wakefield D
    Aust N Z J Med; 1989 Apr; 19(2):118-24. PubMed ID: 2764813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of complement components C1q, C3, C4 and C5 to a model immune complex in ELISA.
    Larsson A; Sjöquist J
    J Immunol Methods; 1989 Apr; 119(1):103-9. PubMed ID: 2785142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fc- and complement receptor-dependent degradation of soluble immune complexes and stable immunoglobulin aggregates by guinea pig monocytes, peritoneal macrophages, and Kupffer cells.
    Daha MR; van Es LA
    J Leukoc Biol; 1984 Nov; 36(5):569-79. PubMed ID: 6593389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods to detect and quantitate complement activation.
    Cooper NR; Nemerow GR; Mayes JT
    Springer Semin Immunopathol; 1983; 6(2-3):195-212. PubMed ID: 6195745
    [No Abstract]   [Full Text] [Related]  

  • 18. Depressed classical complement pathway activities in chronic lymphocytic leukaemia.
    Füst G; Czink E; Minh D; Miszlay Z; Varga L; Hollán SR
    Clin Exp Immunol; 1985 Jun; 60(3):489-95. PubMed ID: 4017286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement activation during an active cytomegalovirus infection after renal transplantation: due to circulating immune complexes or alternative pathway activation?
    van Son WJ; van der Bij W; Tegzess AM; Anema J; van der Giessen M; van der Hem GK; Marrink J; The TH
    Clin Immunol Immunopathol; 1989 Jan; 50(1 Pt 1):109-21. PubMed ID: 2535976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.